Patterns of erythropoiesis-stimulating agent use among Medicare beneficiaries with myelodysplastic syndromes and consistency with clinical guidelines

Leukemia Research

Volumn 37, Issue 6, 2013, Pages 675-680

  Davidoff, Amy J ^a   Weiss, Sheila R ^b,c   Baer, Maria R ^c,d   Ke, Xuehua ^b   Hendrick, Franklin ^b   Zeidan, Amer ^e   Gore, Steven D ^e  

^a AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Erythropoiesis stimulating agent; Guideline adherence; Medicare; Myelodysplastic syndrome; Supportive care

Indexed keywords

ERYTHROPOIETIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ARTICLE; CANCER REGISTRY; CONTROLLED STUDY; HEALTH CARE QUALITY; HUMAN; INSURANCE; MEDICARE; MYELODYSPLASTIC SYNDROME; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; RISK FACTOR; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; DRUG UTILIZATION; ERYTHROPOIETIN; FEMALE; GUIDELINE ADHERENCE; HEMATINICS; HUMANS; MALE; MEDICARE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; RECOMBINANT PROTEINS; REGISTRIES; UNITED STATES;

EID: 84877051972     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.02.021     Document Type: Article

References (37)

1. Melchert M., List A.F. Management of RBC-transfusion dependence. Hematol Am Soc Hematol Educ Program 2007, 398-404.
2. Howe R.B., Porwit-MacDonald A., Wanat R., Tehranchi R., Hellström-Lindberg E. The WHO classification of MDS does make a difference. Blood 2004, 103:3265-3270.
3. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
4. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Drugs@FDA drug information database. (accessed 05.09.11). http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails.
5. Hellström-Lindberg E., Ahlgren T., Beguin Y., Carlsson M., Carneskog J., Dahl I.M., et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 1998, 92:68-75.
6. Negrin R., Stein R., Doherty K., Cornwell J., Vardiman J., Krantz S., et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 1996, 87:4076-4081.
7. Golshayan A.R., Jin T., Maciejewski J., Fu A.Z., Bershadsky B., Kattan M.W., et al. Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes. Br J Haematol 2007, 137:125-132.
8. Sekeres M.A., Schoonen W.M., Kantarjian H., List A., Fryzek J., Paquette R., et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst 2008, 100:1542-1551.
9. National Comprehensive Cancer Network. NCCN GuidelinesTM version 2.2011 updates myelodysplastic syndromes. (accessed 05.09.11). Archived versions of the guidelines from 2001 and 2006 were obtained from the NCCN. http://www.nccn.org/professionals/physician_gls/pdf/mds.pdf.
10. Alessandrino E.P., Amadori S., Barosi G., Cazzola M., Grossi A., Liberato L.N., et al. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica 2002, 87:1286-1306.
11. Bowen D., Culligan D., Jowitt S., Kelsey S., Mufti G., Oscier D., et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 2003, 120:187-200.
12. Jädersten M., Malcovati L., Dybedal I., Della Porta M.G., Invernizzi R., Montgomery S.M., et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 2008, 26:3607-3613.
13. Hellström-Lindberg E., Gulbrandsen N., Lindberg G., Ahlgren T., Dahl I.M., Dybedal I., et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin+granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003, 120:1037-1046.
14. Oliva E.N., Nobile F., Alimena G., Specchia G., Danova M., Rovati B., et al. Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life. Leuk Lymphoma 2010, 51:1007-1014.
15. Bach P.B. Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med 2009, 360:626-633.
16. Warren J.L., Klabunde C.N., Schrag D., Bach P.B., Riley G.F. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002, 40(Suppl. IV). IV-3-IV-18.
17. Rollison D.E., Howlader N., Smith M.T., Strom S.S., Merritt W.D., Ries L.A., et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008, 112:45-52.
18. Weiss Smith S., Sato M., Gore S.D., Baer M.R., Ke X., McNally D., et al. Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes. Haematologica 2012, 97:15-20.
19. Davidoff A.J., Weiss Smith S., Baer M.R., Ke X., Bierenbaum J.M., Hendrick F., et al. Patient and physician characteristics associated with erythropoiesis-stimulating agent use in patients with myelodysplastic syndromes. Haemotogica 2012, 97:128-132.
20. Hess G., Hill J., Clough J., Hulnick S., Nordyke R.J. Utilization of darbepoetin alfa in relation to cancer patients' hemoglobin levels. Curr Med Res Opin 2008, 24:815-819.
21. Nordstrom B.L., Luo W., Fraeman K., Whyte J.L., Nordyke R.J. Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter. J Manage Care Pharm 2008, 14:858-869.
22. Luo W., Nordstrom B.L., Fraeman K., Nordyke R., Ranganathan G., Linz H.E., et al. Adherence to guidelines for use of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia: results of a retrospective study of an electronic medical-records database in the United States, 2002-2006. Clin Ther 2008, 30:2423-2435.
23. Wright J.D., Neugut A.I., Wilde E.T., Buono D.L., Malin J., Tsai W.Y., et al. Physician characteristics and variability of erythropoiesis-stimulating agent use among Medicare patients with cancer. J Clin Oncol 2011, 29:3408-3418.
24. Warren J.L., Harlan L.C., Fahey A., Virnig B.A., Freeman J.L., Klabunde C.N., et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care 2002, 40(Suppl. IV). IV-55-61.
25. MedPage Today. Anemia drugs' marketing in congressional crosshairs. (accessed 05.09.11). http://www.medpagetoday.com/ProductAlert/Prescriptions/8991.
26. Abel G.A., Penson R.T., Joffe S., Schapira L., Chabner B.A., Lynch T.J. Direct-to-consumer advertising in oncology. Oncologist 2006, 11:217-226.
27. Adams J.R., Elting L.S., Lyman G.H., George J.N., Lembersky B.C., Armitage J.O., et al. Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countries. Am J Med 2004, 116:28-34.
28. Cotter D., Thamer M., Narasimhan K., Zhang Y., Bullock K. Translating epoetin research into practice: the role of government and the use of scientific evidence. Health Aff (Millwood) 2006, 25:1249-1259.
29. Leyland-Jones B., Semiglazov V., Pawlicki M., Pienkowski T., Tjulandin S., Manikhas S., et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005, 23:5960-5972.
30. Henke M., Laszig R., Rübe C., Schäfer U., Haase K.D., Schilcher B., et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003, 362:1255-1260.
31. Danish Head and Neck Cancer Group. Interim Analysis of DAHANCA 10, study of the importance of Novel Erythropoiesis Stimulating Protein (Aranesp®) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck. (accessed 05.09.11). http://www.dahanca.dk/get_media_file.php?mediaid=125.
32. Ross S.D., Allen I.E., Henry D.H., Seaman C., Sercus B., Goodnough L.T. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature. Clin Ther 2006, 28:801-831.
33. Bennett C.L., Silver S.M., Djulbegovic B., Samaras A.T., Blau C.A., Gleason K.J., et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008, 299:914-924.
34. Steensma D.P. Erythropoiesis-stimulating agents are effective in myelodysplastic syndromes, but are they safe?. Am J Hematol 2009, 84:3-5.
35. Greenberg P.L., Sun Z., Miller K.B., Bennett J.M., Tallman M.S., Dewald G., et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood 2009, 114:2393-2400.
36. Centers for Medicare and Medicaid Services. National Coverage Determination (NCD) for Erythropoiesis Stimulating Agents (ESAs) in Cancer and Related Neoplastic Conditions (110.21). (accessed 15011.12). http://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx%3FNCDId=322%26ncdver=1%26bc=AAAAQAAAAAAA%26.
37. U.S. Food and Drug Administration. FDA Drug Safety Communication: Erythropoiesis-Stimulating Agents (ESAs): Procrit, Epogen and Aranesp. (accessed 05.09.11). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm200297.htm.